{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:05:18Z","timestamp":1790111118192,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.05.013","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:37:42Z","timestamp":1779899862000},"page":"819-826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of ETI therapy on bone health, body composition and cardiopulmonary fitness in children with CF"],"prefix":"10.1016","volume":"25","author":[{"given":"A","family":"Holden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Devenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0025-5962","authenticated-orcid":false,"given":"L","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6069-1914","authenticated-orcid":false,"given":"R","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jcf.2026.05.013_bib0001","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","article-title":"A Comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto","volume":"41","author":"Corey","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jcf.2026.05.013_bib0002","unstructured":"UK Cystic Fibrosis Registry 2024 Annual Data Report [Internet]. Cystic fibrosis trust. 2025 [cited 2026 Jan 8]. Available from: https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2025-12\/2024%20Registry%20Report%20v2.pdf."},{"issue":"3","key":"10.1016\/j.jcf.2026.05.013_bib0003","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa890","article-title":"The effects of ivacaftor on bone density and microarchitecture in children and adults with cystic fibrosis","volume":"106","author":"Putman","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.013_bib0004","article-title":"Cystic fibrosis bone disease: pathophysiology, assessment and prognostic implications","volume":"18","author":"Anabtawi","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.05.013_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2019.07.073","article-title":"Bone health in children and youth with cystic fibrosis: a systematic review and meta-analysis of matched cohort studies","volume":"215","author":"Ubago-Guisado","year":"2019","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2026.05.013_bib0006","article-title":"Body composition in individuals with cystic fibrosis","volume":"26","author":"Soltman","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.013_bib0007","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jbspin.2015.04.021","article-title":"Body composition, lung function, and prevalent and progressive bone deficits among adults with cystic fibrosis","volume":"83","author":"Baker","year":"2015","journal-title":"Jt Bone Spine"},{"issue":"4","key":"10.1016\/j.jcf.2026.05.013_bib0008","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/resp.12954","article-title":"Physiological markers of exercise capacity and lung disease severity in cystic fibrosis","volume":"22","author":"Smith","year":"2016","journal-title":"Respirol"},{"issue":"8","key":"10.1016\/j.jcf.2026.05.013_bib0009","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1164\/rccm.201806-1110OC","article-title":"Cardiopulmonary exercise testing provides additional prognostic information in cystic fibrosis","volume":"199","author":"Hebestreit","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2026.05.013_bib0010","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1183\/09031936.06.00128605","article-title":"Physical activity is independently related to aerobic capacity in cystic fibrosis","volume":"28","author":"Hebestreit","year":"2006","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.013_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.04.010","article-title":"Changes in exercise capacity in people with cystic fibrosis after one year of elexacaftor\/tezacaftor\/ivacaftor treatment \u2013 a danish prospective cohort","volume":"23","author":"Philipsen","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"19","key":"10.1016\/j.jcf.2026.05.013_bib0012","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jcf.2026.05.013_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080098","article-title":"Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease","volume":"8","author":"Stalvey","year":"2013","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.jcf.2026.05.013_bib0014","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1042\/CS20170995","article-title":"Improvement in exercise duration, lung function and well-being in G551D-cystic Fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment","volume":"131","author":"Edgeworth","year":"2017","journal-title":"Clin Sci"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.013_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.26243","article-title":"Effect of trikafta on bone density, body composition and exercise capacity in CF: a Pilot Study","volume":"58","author":"Gur","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"10.1016\/j.jcf.2026.05.013_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71280","article-title":"Elexacaftor\/tezacaftor\/ivacaftor effect on bone density and body composition: a retrospective analysis","volume":"60","author":"Trost","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jcf.2026.05.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/s41430-025-01589-y","article-title":"A systematic review of the impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in people with cystic fibrosis","volume":"79","author":"Kinsey","year":"2025","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.013_bib0018","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jocd.2021.01.012","article-title":"Evaluation of body composition in paediatric osteogenesis imperfecta","volume":"25","author":"Gilani","year":"2022","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jcf.2026.05.013_bib0019","series-title":"UK-WHO growth charts - 2-18 years [Internet]. Royal college of paediatrics and child health","year":"2018"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.013_bib0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of Spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.013_bib0021","first-page":"172","article-title":"Bone metabolism in children and adolescents: main characteristics of the determinants of peak bone mass","volume":"10","author":"Stagi","year":"2014","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.013_bib0022","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1038\/s41598-024-59622-2","article-title":"Elexacaftor\/tezacaftor\/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis","volume":"14","author":"Westh\u00f6lter","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2026.05.013_bib0023","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clnu.2025.09.008","article-title":"Body mass, linear growth, and body composition before and after the introduction of elexacaftor\/tezacaftor\/ivacaftor among children and adults with cystic fibrosis","volume":"54","author":"Bader-Larsen","year":"2025","journal-title":"Clin Nutr"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.013_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27463","article-title":"Growth, body composition, and strength of children with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor (ETI)","volume":"60","author":"Boat","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"10.1016\/j.jcf.2026.05.013_bib0025","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/ppul.26078","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor improves exercise capacity in adolescents with cystic fibrosis","volume":"57","author":"Causer","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.013_bib0026","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-024-03069-8","article-title":"The long-term effect of elexacaftor\/tezacaftor\/ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: a pilot observational study","volume":"24","author":"Stastna","year":"2024","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jcf.2026.05.013_bib0027","article-title":"Limited impact of elexacaftor\/tezacaftor\/ivacaftor on CPET outcomes in an italian cohort of people with cystic fibrosis: reinforcing the essential role of exercise training","author":"Retucci","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.05.013_bib0028","volume":"61","author":"P\u00e9rez-Ruiz","year":"2025"},{"issue":"11","key":"10.1016\/j.jcf.2026.05.013_bib0029","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1002\/ppul.25038","article-title":"Physical activity in children and adolescents with cystic fibrosis: a systematic review and meta-analysis","volume":"55","author":"Puppo","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.013_bib0030","first-page":"310","article-title":"The relationship between body composition, dietary intake, physical activity, and pulmonary status in adolescents and adults with cystic fibrosis","volume":"14","author":"Scully","year":"2022","journal-title":"Nutrition"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932601636X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932601636X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:07:53Z","timestamp":1790107673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932601636X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S156919932601636X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.013","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of ETI therapy on bone health, body composition and cardiopulmonary fitness in children with CF","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}